# Phase 1 Leukemia, Myeloid, Acute trials: 177 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 177 trials in phase 1 for Leukemia, Myeloid, Acute that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Leukemia, Myeloid, Acute trials: 177 rows for $8.85, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/leukemia-myeloid-acute

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 177
- Recruiting or not yet: 177
- Read on: November 19, 2026

## Trials

The 25 newest of 177, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 2, 2026 | NCT07909733 | Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | University of Wisconsin, Madison | Phase 1 | Not yet recruiting | High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909733) |
| October 29, 2026 | NCT07905027 | A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML | Seattle Children's Hospital | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905027) |
| October 27, 2026 | NCT07897136 | CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897136) |
| September 25, 2026 | NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841002) |
| September 18, 2026 | NCT07828535 | Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828535) |
| September 10, 2026 | NCT07814339 | Hydrochloroquinine & Decitabine With Venetoclax in AML | Rutgers, The State University of New Jersey | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814339) |
| August 21, 2026 | NCT07780565 | Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780565) |
| August 11, 2026 | NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison | Phase 1 | Recruiting | Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758218) |
| August 7, 2026 | NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | Charm Therapeutics | Phase 1 | Recruiting | AML (Acute Myeloid Leukemia) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751991) |
| July 30, 2026 | NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or... | University of Michigan Rogel Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737769) |
| July 23, 2026 | NCT07723703 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML | Amphista Therapeutics Ltd | Phase 1 | Recruiting | Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723703) |
| July 23, 2026 | NCT07722767 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | Cullinan Therapeutics Inc. | Phase 1 | Not yet recruiting | AML (Acute Myeloid Leukemia) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722767) |
| June 25, 2026 | NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | iCell Gene Therapeutics | Phase 1 | Recruiting | Acute Myeloid Leukemia (AML) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668557) |
| June 22, 2026 | NCT07661095 | A Study of CRD3874-SI in People With Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, AML, Refractory Acute Myeloid Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661095) |
| June 12, 2026 | NCT07645469 | FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia | Fred Hutchinson Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645469) |
| June 1, 2026 | NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | Washington University School of Medicine | Phase 1 | Recruiting | Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617363) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 13, 2026 | NCT07583303 | BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1... | City of Hope Medical Center | Phase 1 | Not yet recruiting | Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583303) |
| May 7, 2026 | NCT07573111 | Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem... | Laguna Biotherapeutics, Inc. | Phase 1 | Recruiting | Acute Leukemia, Myelodysplastic Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573111) |
| May 4, 2026 | NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS)... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565220) |
| April 24, 2026 | NCT07551037 | Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy | Fujian Medical University Union Hospital | Phase 1 | Recruiting | Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551037) |
| April 24, 2026 | NCT07549464 | Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549464) |
| April 23, 2026 | NCT07548983 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic... | OHSU Knight Cancer Institute | Phase 1 | Recruiting | Acute Myeloid Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548983) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 11 |
| City of Hope Medical Center | 10 |
| Dana-Farber Cancer Institute | 5 |
| National Cancer Institute (NCI) | 5 |
| Institute of Hematology & Blood Diseases Hospital, China | 5 |
| Memorial Sloan Kettering Cancer Center | 4 |
| St. Jude Children's Research Hospital | 3 |
| Kura Oncology, Inc. | 3 |
| Montefiore Medical Center | 3 |
| OHSU Knight Cancer Institute | 3 |
| Fred Hutchinson Cancer Center | 3 |
| University of Wisconsin, Madison | 3 |
| Stanford University | 3 |
| Seattle Children's Hospital | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| The First Affiliated Hospital of Xiamen University | 2 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Massachusetts General Hospital | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 2 |
| Hangzhou Weben Pharma Co., Ltd | 1 |
| Nuwacell Biotechnologies Co., Ltd. | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 122 |
| China | 36 |
| Spain | 5 |
| Australia | 5 |
| France | 4 |
| United Kingdom | 4 |
| Italy | 3 |
| Germany | 3 |
| Taiwan | 2 |
| Belgium | 2 |
| South Korea | 2 |
| Armenia | 2 |
| Bulgaria | 2 |
| Lithuania | 2 |
| Poland | 2 |
| Romania | 2 |
| Slovakia | 2 |
| Denmark | 1 |
| Russia | 1 |
| Uzbekistan | 1 |
| Netherlands | 1 |
| Canada | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Education services in the United States](https://specstream.ai/data/businesses/education-services/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Social security law firms in the United States](https://specstream.ai/data/businesses/social-security-law-firms/united-states)
- [Paving contractors in the United States](https://specstream.ai/data/businesses/paving-contractors/united-states)
- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
